• Explore /
  • Poster
  • / Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations.

Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations.

Abstract Poster

Authors

null

Kelly N. Fitzgerald

Memorial Sloan Kettering Cancer Center, New York, NY

Kelly N. Fitzgerald , Cihan Duzgol , Andrea Knezevic , Natalie Shapnik , Ritesh Kotecha , David Henry Aggen , Maria Isabel Carlo , Neil J. Shah , Martin H Voss , Darren R. Feldman , Robert J. Motzer , Chung-Han Lee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4536)

DOI

10.1200/JCO.2022.40.16_suppl.4536

Abstract #

4536

Poster Bd #

27

Abstract Disclosures

Similar Posters

First Author: Kelly N. Fitzgerald

First Author: Audreylie Lemelin

First Author: Shaan Dudani

First Author: Maria Cruz Martin Soberón